FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017706891> ?p ?o ?g. }

• W2017706891 endingPage "140" @default.
• W2017706891 startingPage "133" @default.
• W2017706891 abstract "Between January 1989 and November 1995, 259 patients with multiple myeloma (MM), 22 stage I, 57 stage II and 180 stage III at diagnosis were treated with myeloablative high-dose therapy followed by autologous peripheral blood stem cell (PBSC) transplantation. The median time from diagnosis to transplantation was 17 months (6-112). At the time of transplant, 56 patients were in CR, 153 in PR, 25 were nonresponders and 25 had progressive disease. Mobilization of stem cells was performed with G-CSF alone in 141 cases, chemotherapy plus G-CSF in 65, chemotherapy plus GM-CSF in 36 and chemotherapy alone in 17 patients. The conditioning regimen consisted of high-dose melphalan alone in 96 patients, melphalan plus TBI in 73, busulfan plus melphalan in 56, busulfan plus cyclophosphamide in 27 and cyclophosphamide plus TBI in seven. The median durations of neutropenia (>0.5 x 10(9)/l) and thrombocytopenia (>20 x 10(9)/l) were 12 (5-118) and 13 days (5-360), respectively. Transplant-related mortality occurred in 11 patients (4%). Once a stable graft was achieved, 114 patients (44%) received maintenance treatment with recombinant alpha interferon (IFN-alpha). Among the 248 patients evaluable for response 125 (51%) had a CR and 100 had a PR (40%). The median duration of progression-free survival (PFS) and overall survival (OS) after transplantation was 23 and 35 months, respectively. Univariate analysis showed that response status pretransplant, only one line of primary induction treatment and IFN-alpha maintenance treatment post-transplant significantly influenced OS. Female sex, pretransplant responsive disease, and treatment with IFN-alpha post-transplant were the factors significantly influencing PFS. The conditioning regimen and method of stem cell mobilization had no significant impact on OS and PFS. On multivariate analysis the only independent factors associated with a longer survival were the number of chemotherapy courses prior to autologous PBSC transplantation and the pretransplant response status. The present analysis from the Spanish Registry confirms the feasibility of autologous PBSC transplantation in myeloma patients with a very low toxicity (4% toxic deaths). The high complete response rate after transplantation is encouraging. The best results are obtained when the procedure is performed early after the first line of induction therapy and in patients with chemosensitive disease. Whether early high-dose therapy followed by autotransplantation in responding patients is superior to conventional chemotherapy is currently being investigated in prospective randomized studies." @default.
• W2017706891 created "2016-06-24" @default.
• W2017706891 creator A5003780767 @default.
• W2017706891 creator A5018662284 @default.
• W2017706891 creator A5020989412 @default.
• W2017706891 creator A5022691183 @default.
• W2017706891 creator A5025735313 @default.
• W2017706891 creator A5031837957 @default.
• W2017706891 creator A5032722606 @default.
• W2017706891 creator A5033439485 @default.
• W2017706891 creator A5034430204 @default.
• W2017706891 creator A5035799376 @default.
• W2017706891 creator A5039448014 @default.
• W2017706891 creator A5039702098 @default.
• W2017706891 creator A5043277079 @default.
• W2017706891 creator A5045740475 @default.
• W2017706891 creator A5050767282 @default.
• W2017706891 creator A5054913221 @default.
• W2017706891 creator A5056460838 @default.
• W2017706891 creator A5057241518 @default.
• W2017706891 creator A5068024530 @default.
• W2017706891 creator A5075722788 @default.
• W2017706891 creator A5081168775 @default.
• W2017706891 creator A5082366310 @default.
• W2017706891 creator A5084392647 @default.
• W2017706891 creator A5087171473 @default.
• W2017706891 creator A5087767481 @default.
• W2017706891 date "1998-01-01" @default.
• W2017706891 modified "2023-10-18" @default.
• W2017706891 title "Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry" @default.
• W2017706891 doi "https://doi.org/10.1038/sj.bmt.1701062" @default.
• W2017706891 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9489629" @default.
• W2017706891 hasPublicationYear "1998" @default.
• W2017706891 type Work @default.
• W2017706891 sameAs 2017706891 @default.
• W2017706891 citedByCount "82" @default.
• W2017706891 countsByYear W20177068912013 @default.
• W2017706891 countsByYear W20177068912014 @default.
• W2017706891 countsByYear W20177068912016 @default.
• W2017706891 countsByYear W20177068912017 @default.
• W2017706891 countsByYear W20177068912020 @default.
• W2017706891 countsByYear W20177068912021 @default.
• W2017706891 crossrefType "journal-article" @default.
• W2017706891 hasAuthorship W2017706891A5003780767 @default.
• W2017706891 hasAuthorship W2017706891A5018662284 @default.
• W2017706891 hasAuthorship W2017706891A5020989412 @default.
• W2017706891 hasAuthorship W2017706891A5022691183 @default.
• W2017706891 hasAuthorship W2017706891A5025735313 @default.
• W2017706891 hasAuthorship W2017706891A5031837957 @default.
• W2017706891 hasAuthorship W2017706891A5032722606 @default.
• W2017706891 hasAuthorship W2017706891A5033439485 @default.
• W2017706891 hasAuthorship W2017706891A5034430204 @default.
• W2017706891 hasAuthorship W2017706891A5035799376 @default.
• W2017706891 hasAuthorship W2017706891A5039448014 @default.
• W2017706891 hasAuthorship W2017706891A5039702098 @default.
• W2017706891 hasAuthorship W2017706891A5043277079 @default.
• W2017706891 hasAuthorship W2017706891A5045740475 @default.
• W2017706891 hasAuthorship W2017706891A5050767282 @default.
• W2017706891 hasAuthorship W2017706891A5054913221 @default.
• W2017706891 hasAuthorship W2017706891A5056460838 @default.
• W2017706891 hasAuthorship W2017706891A5057241518 @default.
• W2017706891 hasAuthorship W2017706891A5068024530 @default.
• W2017706891 hasAuthorship W2017706891A5075722788 @default.
• W2017706891 hasAuthorship W2017706891A5081168775 @default.
• W2017706891 hasAuthorship W2017706891A5082366310 @default.
• W2017706891 hasAuthorship W2017706891A5084392647 @default.
• W2017706891 hasAuthorship W2017706891A5087171473 @default.
• W2017706891 hasAuthorship W2017706891A5087767481 @default.
• W2017706891 hasBestOaLocation W20177068911 @default.
• W2017706891 hasConcept C126322002 @default.
• W2017706891 hasConcept C141071460 @default.
• W2017706891 hasConcept C2776364478 @default.
• W2017706891 hasConcept C2776694085 @default.
• W2017706891 hasConcept C2776755627 @default.
• W2017706891 hasConcept C2777063308 @default.
• W2017706891 hasConcept C2777408962 @default.
• W2017706891 hasConcept C2778684742 @default.
• W2017706891 hasConcept C2779050716 @default.
• W2017706891 hasConcept C2779263901 @default.
• W2017706891 hasConcept C2780611847 @default.
• W2017706891 hasConcept C2911091166 @default.
• W2017706891 hasConcept C71924100 @default.
• W2017706891 hasConcept C90924648 @default.
• W2017706891 hasConceptScore W2017706891C126322002 @default.
• W2017706891 hasConceptScore W2017706891C141071460 @default.
• W2017706891 hasConceptScore W2017706891C2776364478 @default.
• W2017706891 hasConceptScore W2017706891C2776694085 @default.
• W2017706891 hasConceptScore W2017706891C2776755627 @default.
• W2017706891 hasConceptScore W2017706891C2777063308 @default.
• W2017706891 hasConceptScore W2017706891C2777408962 @default.
• W2017706891 hasConceptScore W2017706891C2778684742 @default.
• W2017706891 hasConceptScore W2017706891C2779050716 @default.
• W2017706891 hasConceptScore W2017706891C2779263901 @default.
• W2017706891 hasConceptScore W2017706891C2780611847 @default.
• W2017706891 hasConceptScore W2017706891C2911091166 @default.
• W2017706891 hasConceptScore W2017706891C71924100 @default.
• W2017706891 hasConceptScore W2017706891C90924648 @default.
• W2017706891 hasIssue "2" @default.

• next